natgillin/translations-raw huggingface dataset:
What is the risk associated with Cialis? 
Kakšna tveganja so povezana z zdravilom Cialis?
Cialis given at a dose of 5 mg was also more effective than placebo in all the studies in patients with benign prostatic hyperplasia, with the results showing a significant improvement in symptoms after 12 weeks compared with placebo. 
Prav tako je bilo zdravilo Cialis, vzeto v 5-miligramskem odmerku, učinkovitejše od placeba v vseh študijah z bolniki z benigno hiperplazijo prostate, pri čemer so rezultati pokazali na znatno izboljšanje simptomov po 12 tednih v primerjavi s placebom.
Cialis is used to treat men with erectile dysfunction (sometimes called impotence) when they cannot get, or keep, a hard penis (erection) sufficient for satisfactory sexual activity. 
Zdravilo Cialis se uporablja za zdravljenje erektilne disfunkcije (imenovane tudi impotenca) pri moških, kadar ne zmorejo doseči ali ohraniti takšne erekcije penisa, ki omogoča zadovoljivo spolno aktivnost.
The active substance of Cialis, tadalafil, belongs to a group of medicines called 'phosphodiesterase type 5 (PDE5) inhibitors'. 
Zdravilna učinkovina v zdravilu Cialis, tadalafil, spada v skupino zdravil imenovanih zaviralci fosfodiesteraze tipa 5 (PDE5).
For treating erectile dysfunction, the recommended dose of Cialis is 10 mg taken ‘on demand' at least 30 minutes before sexual activity. 
Priporočeni odmerek zdravila Cialis za zdravljenje erektilne disfunkcije je 10 mg, vzame pa se „po potrebi“ vsaj 30 minut pred spolno aktivnostjo.
It works by blocking the phosphodiesterase enzyme, which normally breaks down a substance known as cyclic guanosine monophosphate (cGMP). 
Deluje tako, da zavira encim fosfodiesterazo, ki običajno razgrajuje snov, imenovano ciklični gvanozin-monofosfat (cGMP).
During normal sexual stimulation, cGMP is produced in the penis, where it causes the muscle in the spongy tissue of the penis (the corpora cavernosa) to relax, allowing the flow of blood into the corpora, producing the erection. 
Med normalno spolno stimulacijo cGMP nastaja v penisu, kjer povzroči, da se gobasto tkivo penisa (corpora cavernosa) sprosti, kar omogoči dotok krvi v tkivo in posledično erekcijo.
Cialis is a medicine containing the active substance tadalafil. 
Cialis je zdravilo, ki vsebuje zdravilno učinkovino tadalafil.
By blocking the phosphodiesterase enzyme and preventing the breakdown of cGMP, Cialis also improves the blood flow to, and relaxes the muscles of, the prostate and bladder. 
Z zaviranjem encima fosfodiesteraze in preprečevanjem razgradnje cGMP zdravilo Cialis prav tako izboljša pretok krvi v prostato in mehur ter sprosti tamkajšnje mišice.
Cialis must not be taken with nitrates (a type of medicine used for angina) or medicines of the class ‘guanylate cyclase stimulators' such as riociguat (a medicine for high blood pressure in the vessels supplying the lungs, known as pulmonary hypertension). 
Zdravilo se ne sme jemati z nitrati (vrsto zdravil za zdravljenje angine pektoris) ali z zdravili razreda spodbujevalcev gvanilat ciklaze, kot je riocigvat (zdravilo za zdravljenje pljučne hipertenzije, tj. visokega krvnega pritiska v krvnih žilah, ki oskrbujejo pljuča).
For treating men with benign prostatic hyperplasia, or men with both benign prostatic hyperplasia and erectile dysfunction, the recommended dose is 5 mg once a day. 
Priporočeni odmerek za zdravljenje moških z benigno hiperplazijo prostate ali moških z benigno hiperplazijo prostate in erektilno disfunkcijo je 5 mg enkrat na dan.
Four main studies comparing Cialis with placebo were carried out in 1,500 patients with the condition, including some who also had erectile dysfunction. 
Izvedene so bile štiri glavne študije, v katerih so zdravilo Cialis primerjali s placebom pri 1 500 bolnikih s to boleznijo, vključno z nekaterimi, ki so imeli poleg tega tudi erektilno disfunkcijo.
Cialis can also be used in men to treat the signs and symptoms of benign prostatic hyperplasia (enlarged prostate gland that is not cancerous), which involve problems with the flow of urine. 
Zdravilo se lahko uporablja tudi za zdravljenje znakov in simptomov benigne hiperplazije prostate (povečane prostate, ki ni rakava) pri moških, kar vključuje težave v pretoku urina.
Why has Cialis been approved? 
Zakaj je bilo zdravilo Cialis odobreno?
Cialis has also been studied in patients with benign prostatic hyperplasia. 
Zdravilo Cialis so proučevali tudi pri bolnikih z benigno hiperplazijo prostate.
For the full list of all side effects reported with Cialis, see the package leaflet. 
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Cialis, glejte navodilo za uporabo.
Cialis was significantly more effective than placebo in all studies in erectile dysfunction. 
Zdravilo Cialis je bilo v vseh študijah erektilne disfunkcije znatno učinkovitejše od placeba.
However, sexual stimulation is still needed. 
Za učinkovitost zdravila v tem stanju je potrebna spolna stimulacija.
Once-a-day dosing is not recommended in patients with severe kidney problems, and should only be prescribed to patients with liver problems after a careful evaluation of the benefits and risks of taking the medicine. 
Bolniki z resnimi obolenji jeter ali ledvic ne smejo jemati odmerkov, večjih od 10 mg. Odmerjanje zdravila enkrat na dan ni priporočljivo pri bolnikih, ki imajo hude težave z ledvicami, pri bolnikih z obolenji jeter pa se lahko predpiše šele po skrbni oceni koristi in tveganj jemanja zdravila.
Cialis must not be used where sexual activity is inadvisable (e.g. in men with heart disease). 
Zdravila ne smejo uporabljati osebe, ki jim je spolna aktivnost odsvetovana, na primer moški s srčnimi boleznimi.
By blocking the breakdown of cGMP, Cialis restores erectile function. 
Z zaviranjem razgradnje cGMP zdravilo Cialis ponovno vzpostavi erektilno funkcijo, vendar je še vedno potrebna spolna stimulacija.
The maximum recommended dosing frequency is once per day, but continuous daily use of 10 or 20 mg Cialis is not recommended. 
Odmerek se pri moških, ki se ne odzivajo na 10-miligramski odmerek, lahko poveča na 20 mg. Največja priporočena pogostost odmerjanja je enkrat na dan, vendar se odsvetuje dolgo trajajoče vsakodnevno jemanje 10 ali 20-miligramskega odmerka zdravila.
What is Cialis used for? 
Za kaj se zdravilo Cialis uporablja?
How does Cialis work? 
Kako zdravilo Cialis deluje?
How has Cialis been studied? 
Kako je bilo zdravilo Cialis raziskano?
What is Cialis? 
Kaj je zdravilo Cialis?
The dose is 5 mg once a day, but can be lowered to 2.5 mg once a day depending on how well it is tolerated. 
Po presoji zdravnika se pri moških, ki ga nameravajo jemati bolj pogosto (dvakrat tedensko ali pogosteje), zdravilo lahko uporabi enkrat dnevno, vendar v manjšem odmerku, in sicer 5 mg enkrat na dan. Odmerek je mogoče znižati na 2,5 mg enkrat dnevno, odvisno od tega, kako
Cialis, when taken ‘on demand' before sexual activity, has been studied in six main studies including 1,328 patients with erectile dysfunction. 
Zdravilo Cialis so proučevali v šestih glavnih študijah, v katerih je sodelovalo 1 328 bolnikov z erektilno disfunkcijo, ki so zdravilo vzeli „po potrebi“ pred spolno aktivnostjo.
How is Cialis used? 
Kako se zdravilo Cialis uporablja?
The European Commission granted a marketing authorisation valid throughout the European Union for Trevaclyn to Merck Sharp & Dohme Ltd. on 3 July 2008. 
Evropska Komisija je dovoljenje za promet z zdravilom Trevaclyn, veljavno po vsej Evropski uniji, odobrila družbi Merck Sharp & Dohme Ltd. dne 3. julija 2008.
Other information about Trevaclyn: 
Druge informacije o zdravilu Trevaclyn:
Trevaclyn is not recommended for use in children under 18 years of age because of a lack of information on its safety and effectiveness in this group. 
Zdravilo Trevaclyn ni priporočeno za zdravljenje otrok, starih manj kot 18 let, saj ni zadostnih informacij o varnosti in učinkovitosti v tej skupini.
The starting dose of Trevaclyn is one tablet once a day for four weeks, after which the dose is increased to two tablets once a day. 
Začetni odmerek zdravila Trevaclyn je ena tableta enkrat dnevno štiri tedne, nato pa se odmerek poveča na dve tableti enkrat dnevno.
The Committee recommended that Trevaclyn be given marketing authorisation. 
Odbor je priporočil, da se za zdravilo Trevaclyn odobri dovoljenje za promet.
EUROPEAN PUBLIC ASSESSMENT REPORT (EPAR) TREVACLYN EPAR summary for the public 
EVROPSKO JAVNO POROČILO O OCENI ZDRAVILA (EPAR) TREVACLYN Povzetek EPAR za javnost
What benefit has Trevaclyn shown during the studies? 
Kakšne koristi je zdravilo Trevaclyn izkazalo med študijami?
The most common side effect with Trevaclyn (seen in more than 1 patient in 10) is flushing. 
Najpogostejši neželeni učinek zdravila Trevaclyn (opažen pri več kot 1 bolniku od 10) je zardevanje.
Trevaclyn is used on its own only in patients who cannot take statins. 
Zdravilo Trevaclyn se samostojno uporablja samo pri bolnikih, ki ne morejo jemati statina.
The effects of Trevaclyn were first tested in experimental models before being studied in humans. 
Učinki zdravila Trevaclyn so bili najprej preskušeni na poskusnih modelih, nato pa so jih raziskali pri ljudeh.
What is the risk associated with Trevaclyn? 
Kakšna tveganja so povezana z zdravilom Trevaclyn?
Two studies looked at the effectiveness of Trevaclyn in modifying blood fat levels. 
Dve študiji sta preučevali učinkovitost zdravila Trevaclyn pri uravnavanju ravni maščob v krvi.
Trevaclyn is a medicine containing two active substances: nicotinic acid (also known as niacin or vitamin B3) and laropiprant. 
Trevaclyn je zdravilo, ki vsebuje dve zdravilni učinkovini: nikotinsko kislino (znano tudi kot niacin ali vitamin B3) in laropiprant.
Trevaclyn was studied in four main studies in patients with hypercholesterolaemia or mixed dyslipidaemia. 
Zdravilo Trevaclyn so raziskovali v štirih glavnih študijah pri bolnikih s hiperholesterolemijo ali mešano dislipidemijo.
The second study showed that the LDL cholesterol levels were further reduced when Trevaclyn was taken with simvastatin (48% reduction), compared with Trevaclyn alone (17% reduction) or simvastatin alone (37% reduction). 
V drugi študiji so dokazali, da je prišlo še do večjega znižanja ravni LDL-holesterola v skupini, ki je jemala zdravilo Trevaclyn skupaj s simvastatinom (48 % znižanje), v primerjavi s tisto, ki je jemala zdravilo Trevaclyn samostojno (17 % znižanje) ali samo simvastatin (37 % znižanje).
They included a total of 2,349 patients who were taking either Trevaclyn or nicotinic acid. 
Študiji sta vključevali vsega skupaj 2349 bolnikov, ki so jemali zdravilo Trevaclyn ali nikotinsko kislino.
In the first study, LDL cholesterol levels were reduced by 19% in patients taking Trevaclyn, compared with 1% in those taking placebo. 
V prvi študiji so se ravni LDL pri bolnikih, ki so jemali zdravilo Trevaclyn, znižale za 19 % v primerjavi z 1 % pri tistih, ki so jemali placebo.
Trevaclyn is normally given together with a statin (the standard medicine used to reduce cholesterol) when the effectiveness of a statin taken alone is inadequate. 
Zdravilo Trevaclyn se navadno daje skupaj s statinom (standardno zdravilo za zniževanje holesterola), kadar statin samostojno ni dovolj učinkovit.
Trevaclyn should not be used in people who may be hypersensitive (allergic) to nicotinic acid, laropiprant or any of the other ingredients. 
Zdravila Trevaclyn ne smejo uporabljati osebe, ki utegnejo biti preobčutljive za (alergične na) nikotinsko kislino, laropiprant ali katero koli drugo sestavino zdravila.
Why has Trevaclyn been approved? 
Zakaj je bilo zdravilo Trevaclyn odobreno?
For the full list of all side effects reported with Trevaclyn, see the Package Leaflet. 
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Trevaclyn, glejte navodilo za uporabo.
Trevaclyn was effective in reducing the blood levels of LDL cholesterol. 
Zdravilo Trevaclyn je bilo učinkovito pri zniževanju ravni LDL-holesterola.
The two active substances in Trevaclyn, nicotinic acid and laropiprant, have different modes of action. 
Zdravilni učinkovini v zdravilu Trevaclyn, nikotinska kislina in laropiprant, imata različna načina delovanja.
The Committee for Medicinal Products for Human Use (CHMP) decided that Trevaclyn's benefits are greater than its risks for the treatment of dyslipidaemia, particularly in patients with combined mixed dyslipidaemia and in patients with primary hypercholesterolaemia. 
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da so koristi zdravila Trevaclyn pri zdravljenju dislipidemije, zlasti pri bolnikih s kombinirano mešano dislipidemijo in bolnikih s primarno hiperholesterolemijo, večje od z njim povezanih tveganj.
The first study compared the effectiveness of Trevaclyn with that of nicotinic acid alone or placebo (a dummy treatment) in reducing the levels of LDL cholesterol in a total of 1,613 patients. 
V prvi študiji so primerjali učinkovitost zdravila Trevaclyn s samostojno nikotinsko kislino ali placebom (zdravilom brez zdravilne učinkovine) pri zniževanju ravni LDL-holesterola pri vsega skupaj 1613 bolnikih.
In Trevaclyn tablets, laropiprant is in one of the layers, and the other layer contains nicotinic acid. 
En sloj tablet zdravila Travaclyn vsebuje laropiprant, drugi sloj pa vsebuje nikotinsko kislino.
In the fourth study, flushing was seen on fewer days in patients taking Trevaclyn than in those taking nicotinic acid alone. 
V četrti študiji je bilo število dni opaženega zardevanja manjše pri tistih bolnikih, ki so jemali zdravilo Trevaclyn kot pri tistih, ki so jemali samo nikotinsko kislino.
In the first and third studies, fewer patients taking Trevaclyn reported moderate, severe or extreme flushing than patients taking nicotinic acid alone. 
V prvi in tretji študiji je o zmernem, hudem ali skrajnem zardevanju poročalo manj tistih bolnikov, ki so jemali Trevaclyn, kot tistih, ki so jemali samo nikotinsko kislino.
The nicotinic acid is released more slowly from the other layer and has its effect as a fat-modifying agent. 
Nikotinska kislina se iz drugega sloja sprošča počasneje in učinkuje kot sredstvo za uravnavanje maščob v krvi.
Trevaclyn is used in addition to diet and exercise in patients with dyslipidaemia (abnormally high levels of fat in the blood), particularly ‘combined mixed dyslipidaemia' and ‘primary hypercholesterolaemia'. 
Zdravilo Trevaclyn se uporablja kot dodatek k prehrani in telesni vadbi pri bolnikih z dislipidemijo (nenormalno visoka raven maščobe v krvi), zlasti pri tistih s kombinirano mešano dislipidemijo in primarno hiperholesterolemijo.
The full EPAR for Trevaclyn can be found here. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Trevaclyn je na voljo tukaj.
It should be used with caution in patients who have problems with their kidneys and should not be used in patients with liver problems. 
Pri bolnikih z ledvičnimi težavami je potrebna posebna previdnost pri uporabi zdravila Trevaclyn, pri bolnikih z jetrnimi težavami pa se zdravilo Trevaclyn ne sme uporabljati.
How has Trevaclyn been studied? 
Kako je bilo zdravilo Trevaclyn raziskano?
The second study compared the combination of Trevaclyn and simvastatin (a statin) with Trevaclyn alone or simvastatin alone in 1,398 patients. 
V drugi študiji so pri 1398 bolnikih primerjali kombinacijo zdravila Trevaclyn in simvastatin (vrsta statina) s samostojnim zdravilom Trevaclyn ali simvastatinom.
How is Trevaclyn used? 
Kako se zdravilo Trevaclyn uporablja?
What is Trevaclyn used for? 
Za kaj se zdravilo Trevaclyn uporablja?
What is Trevaclyn? 
Kaj je zdravilo Trevaclyn?
How does Trevaclyn work? 
Kako zdravilo Trevaclyn deluje?
Previously known as Arcalyst. 
1 Prej znano kot Arcalyst.
It must not be used in patients with an active, severe infection. 
Zdravilo se ne sme uporabljati pri bolnikih z aktivnimi resnimi okužbami.
It contains the active substance rilonacept (80 mg/ml). 
Vsebuje zdravilno učinkovino rilonacept (80 mg/ml).
Patients may inject themselves once they have been trained if their doctor believes it is appropriate. 
Bolniki si lahko zdravilo injicirajo sami, če so o tem ustrezno poučeni in če njihov zdravnik oceni, da je to primerno.
The European Commission granted a marketing authorisation valid throughout the European Union for Arcalyst to Regeneron UK Limited on 23 October 2009. 
Evropska komisija je dovoljenje za promet z zdravilom Arcalyst, veljavno po vsej Evropski uniji, odobrila družbi Regeneron UK Limited dne 23. oktobra 2009.
Severe disabilities such as deafness and loss of vision may also occur. 
Prav tako lahko pride do resne prizadetosti, kot je naglušnost in izguba vida.
The main measure of effectiveness was how much their symptoms reduced after the six-week treatment and how much the improvements were maintained after the nine-week treatment. 
Glavno merilo učinkovitosti je bila ublažitev simptomov po šesttedenskem zdravljenju in ohranitev tega izboljšanja po koncu devettedenskega zdravljenja.
The starting dose is 4.4 mg per kilogram body weight (up to a maximum of 320 mg), which is followed a week later by once weekly injections of 2.2 mg/kg (up to a maximum of 160 mg). 
Začetni odmerek znaša 4,4 mg na kilogram telesne mase (do največ 320 mg), teden dni za njim pa se začnejo enkrat tedensko dajati injekcije po 2,2 mg/kg (do največ 160 mg).
Five symptoms (rash, fever or chills, joint pain, tiredness and eye redness or pain) were assessed by patients themselves on a scale from 0 to 10 points. 
Pet simptomov (izpuščaji, vročina ali mrzlica, bolečine v sklepih, utrujenost in pordelost oči ali bolečina v očeh) so bolniki ocenjevali sami s točkami od 0 do 10.
The name of the medicine was changed to Rilonacept Regeneron on 23 July 2010. 
Ime zdravila je bilo 23. julija 2010 spremenjeno v Rilonacept Regeneron.
CAPS are a group of diseases where patients have a defect in the gene that produces a protein called cryopyrin. 
CAPS je skupina bolezni, pri katerih imajo bolniki okvaro gena, ki proizvaja beljakovino, imenovano kriopirin.
This means that because the diseases are rare, it has not been possible to obtain complete information about Rilonacept Regeneron. 
To pomeni, da zaradi redkosti bolezni ni mogoče pridobiti vseh informacij o zdravilu Rilonacept Regeneron.
Because the number of patients with CAPS is low, the diseases are considered ‘rare', and Rilonacept Regeneron was designated an ‘orphan medicine' (a medicine used in rare diseases) on 10 July 2007. 
Ker je število bolnikov s CAPS majhno, veljajo te bolezni za redke, zato je bilo zdravilo Rilonacept Regeneron 10. julija 2007 določeno kot „zdravilo sirota“ (zdravilo, ki se uporablja pri redkih boleznih).
This document is a summary of the European public assessment report (EPAR) for Rilonacept Regeneron. 
Ta dokument je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Rilonacept Regeneron.
Rilonacept Regeneron has been authorised under ‘exceptional circumstances'. 
Zdravilo Rilonacept Regeneron je bilo odobreno „v izjemnih okoliščinah“.
The full EPAR for Rilonacept Regeneron can be found on the Agency's website under EMA website/Find medicine/Human medicines/European Public Assessment Reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Rilonacept Regeneron je na voljo na spletni strani agencije po rubriko EMA website/Find medicine/Human medicines/European Public Assessment Reports.
For more information about treatment with Rilonacept Regeneron, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Rilonacept Regeneron preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte s svojim zdravnikom ali farmacevtom.
The summary of opinion of the Committee for Orphan Medicinal Products for Rilonacept Regeneron is available here. 
Povzetek mnenja Odbora za zdravila sirote za zdravilo Rilonacept Regeneron je na voljo tukaj.
The CHMP decided that Rilonacept Regeneron's benefits are greater than its risks and recommended that it be given marketing authorisation. 
CHMP je zaključil, da so koristi zdravila Rilonacept Regeneron večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
This leads to inflammation in many parts of the body, with symptoms such as fever, rash, joint pain, and tiredness. 
Zaradi tega pride do vnetja na številnih delih telesa s simptomi, kot so vročina, izpuščaji, bolečine v sklepih in utrujenost.
Rilonacept Regeneron should not be used in people who may be hypersensitive (allergic) to rilonacept or any of the other ingredients. 
Zdravila Rilonacept Regeneron ne smejo uporabljati osebe, ki utegnejo biti preobčutljive za (alergične na) rilonacept ali katero koli drugo sestavino zdravila.
The company that makes Rilonacept Regeneron will provide regular information on the safety and effectiveness of Rilonacept Regeneron in adults and children from a registry and will perform a study in children to further investigate what happens to the medicine in the body. 
Družba, ki izdeluje zdravilo Rilonacept Regeneron, bo iz registra pridobila ustrezne informacije o varnosti in učinkovitosti zdravila Rilonacept Regeneron pri odraslih in otrocih ter izvedla študijo pri otrocih, da bo dodatno raziskala, kaj se zgodi z zdravilom v telesu.
Adults should be given a starting dose of two injections of 160 mg each in two different parts of the body on the same day. 
Začetni odmerek pri odraslih je dve injekciji, vsaka po 160 mg, injicirani v dva različna dela telesa isti dan.
The most common side effects with Rilonacept Regeneron (seen in more than 1 patient in 10) are reactions at the injection site, upper respiratory tract infections (colds), sinusitis (inflammation of the sinuses) and headache. 
Najpogostejši neželeni učinki zdravila Rilonacept Regeneron (opaženi pri več kot 1 bolniku od 10) so reakcije na mestu injiciranja, okužbe zgornjih dihal (prehladi), sinusitis (vnetje sinusov) in glavobol.
Patients treated with Rilonacept Regeneron must be given an alert card that summarises the key safety information about the medicine. 
Bolnikom, ki prejemajo zdravilo Rilonacept Regeneron, je treba dati opozorilno kartico, ki povzema najpomembnejše varnostne informacije o zdravilu.
Treatment with Rilonacept Regeneron should be started and supervised by a specialist doctor experienced in diagnosing and treating CAPS. 
Zdravljenje z zdravilom Rilonacept Regeneron mora uvesti in nadzirati zdravnik specialist, ki ima izkušnje z diagnosticiranjem in zdravljenjem CAPS.
After the sixweek treatment, patients who received Rilonacept Regeneron had a reduction in symptoms of 2.5 points on the scale compared with 0.3 points in patients who received placebo. 
Po šestih tednih zdravljenja so se pri bolnikih, ki so prejemali zdravilo Rilonacept Regeneron, simptomi ublažili za 2,5 točke v primerjavi z 0,3 točke pri bolnikih, ki so prejemali placebo.
In the second part of the study, symptoms increased more in patients switched to placebo (0.9 points) compared with patients who remained on Rilonacept Regeneron (0.1 points). 
V drugem delu študije so se simptomi bolj poslabšali pri bolnikih, ki so prešli na placebo (0,9 točke), v primerjavi z bolniki, ki so nadaljevali zdravljenje z zdravilom Rilonacept Regeneron (0,1 točke).
The company that makes Rilonacept Regeneron will provide doctors in all Member States who will use Rilonacept Regeneron with a pack containing the prescribing information, a patient alert card and information for doctors explaining the risk of side effects and how to use the medicine properly. 
Družba, ki izdeluje zdravilo Rilonacept Regeneron, bo zdravnikom v vseh državah članicah, ki uporabljajo zdravilo Rilonacept Regeneron, priskrbela informacije o predpisovanju zdravila, opozorilno kartico za bolnike in informacije za zdravnike, s katerimi bo pojasnila tveganja za neželene učinke in podala informacije o tem, kako zdravilo pravilno uporabljati.
Rilonacept Regeneron is used to treat cryopyrin-associated periodic syndromes (CAPS). 
Zdravilo Rilonacept Regeneron se uporablja za zdravljenje s kriopirinom povezanih periodičnih sindromov (CAPS).